Recombinant Human F13A (C-6His)

Description

EnkiLife provides the Recombinant Human F13A (C-6His) protein,aslo know as Coagulation Factor XIII A Chain,Coagulation Factor XIIIa,Protein-Glutamine Gamma-Glutamyltransferase A Chain,Transglutaminase A Chain,F13A1,F13A, which features high purity, high activity, and high stability. It can be applied in scientific research, biopharmaceuticals, and other fields.Purity:Greater than 95% as determined by reducing SDS-PAGE;Endotoxin Level:<1 EU/µg as determined by LAL test.;Construction:Recombinant Human Coagulation Factor XIII A Chain is produced by our Mammalian expression system and the target gene encoding Gly39-Met732 is expressed with a 6His tag at the C-terminus.Accession:AAH27963.1. Expression Host:Human Cells.Species:Human.Predicted Molecular Mass:80.3 KDa. Background:Coagulation factor XIII is the last zymogen to become activated in the blood coagulation cascade. Plasma factor XIII is a heterotetramer composed of 2 A subunits and 2 B subunits. The A subunits have catalytic function, and the B subunits do not have enzymatic activity and may serve as plasma carrier molecules. Platelet factor XIII is composed of just 2 A subunits, which are identical to those of plasma origin. Upon cleavage of the activation peptide by thrombin and in the presence of calcium ion, the plasma factor XIII dissociates its B subunits and yields the same active enzyme, factor XIIIa, as platelet factor XIII. This enzyme acts as a transglutaminase to catalyze the formation of gamma-glutamyl-epsilon-lysine crosslinking between fibrin molecules, thus stabilizing the fibrin clot. Factor XIII deficiency is classified into two categories: type I deficiency, characterized by the lack of both the A and B subunits; and type II deficiency, characterized by the lack of the A subunit alone. These defects can result in a lifelong bleeding tendency, defective wound healing, and habitual abortion.